FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Richard Ceska

Research Profile

Disorders

Chemicals & Drugs

Concepts & Ideas

Risk Factors

Anatomy

Co-author Network

Publications

TOP 3
L Zlatohlavek; Richard Ceska; D Dlouha; E Motykova; L Vasickova; Michal Vrablik; J A Hubacek
FTO and MC4R gene variants determine BMI changes in children after intensive lifestyle intervention.
L Zlatohlavek; Vera Adamkova; Richard Ceska; M Prusikova; Z Urbanova; L Vasickova; Michal Vrablik; J A Hubacek
APOA5 haplotypes determine triglyceride decrease after lifestyle induced weight loss in children.
Lukas Zlatohlavek; Barbora Grauova; Eva Motykova; Michal Vrablik; Richard Ceska
The effect of coenzyme Q10 in statin myopathy.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Richard Ceska (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: L Zlatohlavek; Richard Ceska; D Dlouha; E Motykova; L Vasickova; Michal Vrablik; J A Hubacek
FTO and MC4R gene variants determine BMI changes in children after intensive lifestyle intervention.
Clinical biochemistry 2013;46(4-5):313-6.
2012: L Zlatohlavek; Vera Adamkova; Richard Ceska; M Prusikova; Z Urbanova; L Vasickova; Michal Vrablik; J A Hubacek
APOA5 haplotypes determine triglyceride decrease after lifestyle induced weight loss in children.
Nutrition, metabolism, and cardiovascular diseases : NMCD 2012;22(9):e22-3.
2012: Lukas Zlatohlavek; Barbora Grauova; Eva Motykova; Michal Vrablik; Richard Ceska
The effect of coenzyme Q10 in statin myopathy.
Neuro endocrinology letters 2012;33 Suppl 2():98-101.
2012: Tomas Stulc; Richard Ceska; Iuri Marinov; Jan Skrha
The effect of simvastatin and fenofibrate on the expression of leukocyte adhesion molecules and lipopolysaccharide receptor CD14 in type 2 diabetes mellitus.
Neuro endocrinology letters 2012;33 Suppl 2():73-7.
2012: Jaroslav A Hubacek; Vera Lanska; Vera Adámkova; Richard Ceska; Dana Dlouha; Michal Vrablik
Possible gene-gender interaction between the SLCO1B1 polymorphism and statin treatment efficacy.
Neuro endocrinology letters 2012;33 Suppl 2():22-5.
2011: Vladimír Soska; Tomas Freiberger; Renata Cifkova; Vera Lanska; Michal Vrablik; Lenka Fajkusova; Richard Ceska
Plasma HDL-cholesterol and triglyceride levels in familial hypercholesterolemia: data from the MedPed CZ database and the Czech population.
Clinica chimica acta; international journal of clinical chemistry 2011;412(11-12):920-4.
2011: Martina Prusikova; Michal Vrablik; Libor Zamecnik; Eva Horova; Vera Lanska; Richard Ceska
Prevalence of risk factors of cardiovascular diseases in men with erectile dysfunction. Are they as frequent as we believe?
Neuro endocrinology letters 2011;32 Suppl 2():60-3.
2011: Eva Motykova; Martina Prusikova; Ludmila Vasickova; Richard Ceska; Vera Lanska; Lukáš Zlatohlavek; Michal Vrablik
Lifestyle modification induced weight loss and changes of cardiometabolic risk factors including lowering of inflammatory response in obese children.
Neuro endocrinology letters 2011;32 Suppl 2():55-9.
2011: Michaela Snejdrlova; Eva Topinkova; Michal Vrablik; Lukas Zlatohlavek; Zdenek Kalvach; Marie Kvasilova; Vera Lanska; Renata Prochazkova; Martina Prusikova; Richard Ceska
APOE polymorphism as a potential determinant of functional fitness in the elderly regardless of nutritional status.
Neuro endocrinology letters 2011;32 Suppl 2():51-4.
2009: Katerina Hirschfeldova; Dana Lipovska; Pavel Skrha; Richard Ceska
The apo(a) gene (TTTTA)n promoter polymorphism and its association with variability in exons of the kringle IV types 8 to 10.
Clinica chimica acta; international journal of clinical chemistry 2009;405(1-2):39-42.
2009: Jaroslav A Hubacek; Vera Adamkova; Martina Prusikova; Michaela Snejdrlova; Katerina Hirschfeldova; Vera Lanska; Richard Ceska; Michal Vrablik
Impact of apolipoprotein A5 variants on statin treatment efficacy.
Pharmacogenomics 2009;10(6):945-50.
2009: E Chytilová; J Malík; Z Kasalová; R Dolezalová; Tomas Stulc; Richard Ceska
Lower wall shear rate of the common carotid artery in treated type 2 diabetes mellitus with metabolic syndrome.
Physiological research / Academia Scientiarum Bohemoslovaca 2009;58(2):185-91.
2008: M Vrablík; T Freiberger; V Lánská; Richard Ceska
[The Atractiv project: improvement of cardiovascular preventive in primary care in the Czech Republic].
Vnitr̆ní lékar̆ství 2008;54(12):1131-9.
2008: Michal Vrablik; Richard Ceska; Vera Adamkova; Anne Peasey; Hynek Pikhart; Ruzena Kubinova; Michael Marmot; Martin Bobak; Jaroslav A Hubacek
MLXIPL variant in individuals with low and high triglyceridemia in white population in Central Europe.
Human genetics 2008;124(5):553-5.
2008: Jean-Charles Fruchart; Frank M Sacks; Michel P Hermans; Gerd Assmann; W Virgil Brown; Richard Ceska; M John Chapman; Paul M Dodson; Paola Fioretto; Henry N Ginsberg; Takashi Kadowaki; Jean-Marc LaBlanche; Nikolaus Marx; Jorge Plutzky; Zeljko Reiner; Robert S Rosenson; Bart Staels; Jane K Stock; Rody Sy; Christoph Wanner; Alberto Zambon; Paul Zimmet
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient.
Diabetes & vascular disease research : official journal of the International Society of Diabetes and Vascular Disease 2008;5(4):319-35.
2008: Michal Vrablik; Tomas Fait; Jan Kovar; Rudolf Poledne; Richard Ceska
Oral but not transdermal estrogen replacement therapy changes the composition of plasma lipoproteins.
Metabolism: clinical and experimental 2008;57(8):1088-92.
2008: Richard Ceska; V Tesar
[Diabetes, dyslipidaemia and kidney diseases].
Vnitr̆ní lékar̆ství 2008;54(5):511-7.
2008: Tomas Stulc; Richard Ceska
Rosiglitazone in the prevention of diabetes and cardiovascular disease: dream or reality?
Medical science monitor : international medical journal of experimental and clinical research 2008;14(4):RA45-7.
2008: Michal Vrablík; Milada Dobiásová; Tomas Stulc; Zdislava Kasalová; R Dolezalová; Martin Prázný; Tomas Fait; Richard Ceska
Fenofibrate and rosiglitazone improve quality of lipoproteins in patients with type 2 diabetes mellitus.
Neuro endocrinology letters 2008;29(1):146-50.
2008: Jaroslav A Hubacek; Wu-Wei Wang; Zdena Skodová; Vera Adámková; Michal Vráblík; Ales Horínek; Tomás Stulc; Richard Ceska; Philippa J Talmud
APOA5 Ala315>Val, identified in patients with severe hypertriglyceridemia, is a common mutation with no major effects on plasma lipid levels.
Clinical chemistry and laboratory medicine : CCLM / FESCC 2008;46(6):773-7.
2008: Richard Ceska
[Medicine in the year 2008: is there light visible at the end of the tunnel!].
Vnitr̆ní lékar̆ství 2008;54(1):5-6.
2008: Lukás Zlatohlávek; Katerina Zídková; Michal Vrablík; Tomas Haas; M Prusíková; H Svobodová; Richard Ceska
Lipoprotein(a) and its position among other risk factors of atherosclerosis.
Physiological research / Academia Scientiarum Bohemoslovaca 2008;57(5):777-83.
2008: J Malík; Tomas Stulc; Dan Wichterle; Vojtech Melenovsky; E Chytilová; Z Lacinová; J Marek; Richard Ceska
Hyperlipidemia is associated with altered levels of insulin-like growth factor-I.
Physiological research / Academia Scientiarum Bohemoslovaca 2008;57(6):919-25.
2008: Tomas Stulc; Richard Ceska
Prevention of diabetes with rosiglitazone: Evidence of benefit or unexpected harm?
Medical hypotheses 2008;70(1):199-200.
2007: Richard Ceska
Clinical implications of the metabolic syndrome.
Diabetes & vascular disease research : official journal of the International Society of Diabetes and Vascular Disease 2007;4 Suppl 3():S2-4.
2007: Katerina Zídková; Lukás Zlatohlávek; Richard Ceska
Variability in apo(a) gene regulatory sequences, compound genotypes, and association with Lp(a) plasma levels.
Clinical biochemistry 2007;40(11):802-5.
2007: Tomás Freiberger; Richard Ceska
[Is familial hypercholesterolemia under control in the Czech Republic?].
Vnitr̆ní lékar̆ství 2007;53(6):703-5, 707-8.
2007: Hana Rosolová; V Bláha; Richard Ceska; Z Hamouz; T Pelikánová; V Soska; Miroslav Soucek; P Sucharda
[The effect of treatment with fenofibrate on the risk profile of patients with metabolic syndrome and mixed dyslipidemia treated on an outpatient basis].
Vnitr̆ní lékar̆ství 2007;53(4):339-46.
2007: Helena Vaverková; V Soska; Hana Rosolová; Richard Ceska; Renata Cífková; Tomás Freiberger; Jan Pit'ha; Rudolf Poledne; Tomas Stulc; Z Urbanová; Michal Vráblík
[Czech Atherosclerosis Society Guidelines for the diagnosis and treatment of dyslipidemias in adults].
Vnitr̆ní lékar̆ství 2007;53(2):181-7, 189, 191-3 passim.
2007: Katerina Zídková; Vera Kebrdlová; Lukás Zlatohlávek; Richard Ceska
Detection of variability in apo(a) gene transcription regulatory sequences using the DGGE method.
Clinica chimica acta; international journal of clinical chemistry 2007;376(1-2):77-81.
2007: Katerina Zídková; Lukás Zlatohlávek; Richard Ceska
[Genetic aspects of high variability of lipoprotein(a) levels].
Casopís lékar̆ů c̆eských 2007;146(8):653-7.
2007: H Svobodová; F Kucera; Tomas Stulc; Michal Vrablík; B Amartuvshin; Ts Altannavch; Richard Ceska
Apolipoprotein E gene polymorphism in the Mongolian population.
Folia biologica 2007;53(4):138-42.
2007: Helena Vaverková; V Soska; Hana Rosolová; Richard Ceska; Renata Cífková; Tomás Freiberger; Jan Pit'ha; Rudolf Poledne; Tomas Stulc; Z Urbanová; Michal Vráblík
[Czech atherosclerosis society guidelines for the diagnosis and treatment of dyslipidemia in adults].
Casopís lékar̆ů c̆eských 2007;146(6):II-XV.
2006: Tomas Stulc; Richard Ceska
Is it safe to combine PPAR agonists? A lesson from muraglitazar.
Medical hypotheses 2006;67(3):669.
2005: Tomas Stulc; Zdislava Kasalova; Hana Krejci; Radka Dolezalova; Richard Ceska
Effect of rosiglitazone on homocysteine and creatinine levels in patients with type 2 diabetes.
Atherosclerosis 2005;183(2):367-8.
2005: Jan Malik; Tomas Stulc; Richard Ceska
Matrix metalloproteinases in isolated hypercholesterolemia.
International angiology : a journal of the International Union of Angiology 2005;24(3):300-3.
2005: Jaroslav A Hubacek; Ales Horínek; Zdena Skodova; Vera Adamkova; Richard Ceska; Lukas Zlatohlavek; Michal Vráblík
Hypertriglyceridemia: interaction between APOE and APOAV variants.
Clinical chemistry 2005;51(7):1311-3.
2005: Jan Vevera; Zdenek Fisar; Tomás Kvasnicka; Hanus Zdenek; Lucie Stárková; Richard Ceska; Hana Papezová
Cholesterol-lowering therapy evokes time-limited changes in serotonergic transmission.
Psychiatry research 2005;133(2-3):197-203.
2005: E Králíková; S Býma; Renata Cífková; Richard Ceska; V Dvorák; J Hamanová; Karel Horký; Jaromir Hradec; O Keller; S Konstacký; S Kos; R Kostrica; M Kunesová; M Kvapil; K Langrová; Otto Mayer; V Petrů; P Popov; J Raboch; Hana Rosolová; K Roztocil; P Sucharda; J Vorlícek; J Widimský
[Recommendations for the treatment of tobacco dependence].
Casopís lékar̆ů c̆eských 2005;144(5):327-33.
2005: Jarmila Sulcová; Tomas Stulc; Martin Hill; Richard Hampl; Z Masek; Karel Vondra; Richard Ceska
Decrease in serum dehydroepiandrosterone level after fenofibrate treatment in males with hyperlipidemia.
Physiological research / Academia Scientiarum Bohemoslovaca 2005;54(2):151-7.
2004: Michal Vrablík; Richard Ceska
New strategies in the treatment of dyslipidemia: do we know how?
Seminars in vascular medicine 2004;4(3):305-10.
2004: H Wilczek; Richard Ceska; Lukás Zlatohlávek
[Serum lipids in drug addicts].
Vnitr̆ní lékar̆ství 2004;50(8):584-6.
2004: Jan Skrha; Tomas Stulc; Jirina Hilgertová; Hana Weiserová; Jan Kvasnicka; Richard Ceska
Effect of simvastatin and fenofibrate on endothelium in Type 2 diabetes.
European journal of pharmacology 2004;493(1-3):183-9.
2004: Jaroslav A Hubácek; Vera Adámková; Richard Ceska; Rudolf Poledne; Ales Horínek; Michal Vráblík
New variants in the apolipoprotein AV gene in individuals with extreme triglyceride levels.
Physiological research / Academia Scientiarum Bohemoslovaca 2004;53(2):225-8.
2003: Tomas Stulc; Ivan Matous Malbohan; Jan Malík; Lenka Fialová; Jirina Soukupová; Richard Ceska
Increased levels of pregnancy-associated plasma protein-A in patients with hypercholesterolemia: the effect of atorvastatin treatment.
American heart journal 2003;146(6):E21.
2003: Tomás Kvasnicka; Jan Kvasnicka; Richard Ceska; Michal Vrablik
Increase of inflammatory state in overweight adults with combined hyperlipidemia.
Nutrition, metabolism, and cardiovascular diseases : NMCD 2003;13(4):227-31.
2003: Michal Vrablík; Ales Horínek; Richard Ceska; Vera Adámková; Rudolf Poledne; Jaroslav A Hubacek
Ser19-->Trp polymorphism within the apolipoprotein AV gene in hypertriglyceridaemic people.
Journal of medical genetics 2003;40(8):e105.
2003: Vojtech Melenovsky; Dan Wichterle; Jan Simek; Jan Malik; Tomas Haas; Richard Ceska; Marek Malik
Effect of atorvastatin and fenofibrate on autonomic tone in subjects with combined hyperlipidemia.
The American journal of cardiology 2003;92(3):337-41.
2003: Vojtech Melenovsky; Tomas Stulc; Viktor Kozich; Barbora Grauova; Jan Krijt; Dan Wichterle; Tomas Haas; Jan Malik; Jaromir Hradec; Richard Ceska
Effect of folic acid on fenofibrate-induced elevation of homocysteine and cysteine.
American heart journal 2003;146(1):110.
2003: Jan Malik; Tomas Stulc; Richard Ceska
Unraveling Reaven's syndrome X: serum insulin-like growth factor-I and cardiovascular disease.
Circulation 2003;107(20):e190-2; author reply e190-2.
2003: Ales Horínek; Michal Vráblík; Richard Ceska; Vera Adámková; Rudolf Poledne; Jaroslav A Hubacek
T-1131-->C polymorphism within the apolipoprotein AV gene in hypertriglyceridemic individuals.
Atherosclerosis 2003;167(2):369-70.
2003: Jaroslav A Hubacek; Zdena Skodova; Vera Adamkova; Michal Vrablik; Ales Horinek; Vera Lanska; Richard Ceska; Rudolf Poledne
Apolipoprotein AV gene polymorphisms (T-1131/C and Ser19/Trp) influence plasma triglyceride levels and risk of myocardial infarction.
Experimental and clinical cardiology 2003;8(3):151-4.
2003: Jirí Spácil; Richard Ceska; Tomas Haas
[Indirect relation between intimo-medial thickness of the carotid artery and vasodilation of the popliteal artery].
Sborník lékar̆ský 2003;104(4):361-8.
2003: Michal Vrablík; Ales Horínek; Richard Ceska; Tomas Stulc; Tomás Kvasnicka
Familial dysbetalipoproteinemia in three patients with apoE 2*(Arg136-->Cys) gene variant.
Physiological research / Academia Scientiarum Bohemoslovaca 2003;52(5):647-50.
2003: Tomas Stulc; Zdislava Kasalová; Martin Prázný; Michal Vrablík; Jan Skrha; Richard Ceska
Microvascular reactivity in patients with hypercholesterolemia: effect of lipid lowering treatment.
Physiological research / Academia Scientiarum Bohemoslovaca 2003;52(4):439-45.
2003: Jean C Lubanda; Stanislaw Simek; Ales Linhart; Michael Aschermann; Richard Ceska
Interventional treatment of multiple vascular involvement in young male with heterozygous familial hypercholesterolemia.
Casopís lékar̆ů c̆eských 2003;142(4):248-51.
2003: Tomas Stulc; Michal Vrablík; Zdislava Kasalová; Richard Ceska; Iuri Marinov
Atorvastatin reduces expression of leukocyte adhesion molecules in patients with hypercholesterolemia.
Atherosclerosis 2003;166(1):197-8.
2003: Richard Ceska; Tomas Stulc; Tomáš Zima; Ivan Matous Malbohan; Lenka Fialova
PAPP-A, a novel marker of unstable plaque, is not influenced by hypolipidemic treatment in contrast to CRP.
Atherosclerosis 2003;166(1):195-6.
2002: Richard Ceska; Tomás Kvasnicka; V Bláha; Jan Pit'ha; V Soska
[Simvor in the treatment of hyperlipoproteinaemia].
Vnitr̆ní lékar̆ství 2002;48(10):966-70.
2002: Vojtech Melenovsky; Jan Malik; Dan Wichterle; Jan Simek; Alexandra Pisarikova; Jan Skrha; Rudolf Poledne; Petr Stavek; Richard Ceska
Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia.
American heart journal 2002;144(4):E6.
2002: Vojtech Melenovsky; Dan Wichterle; Jan Malik; Jan Simek; Jaromir Hradec; Richard Ceska; Marek Malik
Nitroglycerin induced syncope occurs in subjects with delayed phase shift of baroreflex action.
Pacing and clinical electrophysiology : PACE 2002;25(5):828-32.
2002: Jirí Spácil; Richard Ceska; Tomas Haas
[Dilatation of the popliteal artery in hyperemia and intimal-medial thickness of the carotid artery in hyperlipoproteinemia, ischemic heart disease and in healthy individuals].
Sborník lékar̆ský 2002;103(3):305-11.
2001: Jan Malik; Vojtech Melenovsky; Dan Wichterle; Tomas Haas; Jan Simek; Richard Ceska; Jaromir Hradec
Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial--FAT).
Cardiovascular research 2001;52(2):290-8.
2001: Jirí Spácil; Richard Ceska; Tomas Haas
Flow-dependent vasomotor dysfunction of the popliteal artery related to common carotid artery intima-media thickness.
Angiology 2001;52(10):689-95.
2001: Tomas Stulc; Vojtech Melenovsky; B Grauová; Viktor Kozich; Richard Ceska
Folate supplementation prevents plasma homocysteine increase after fenofibrate therapy.
Nutrition (Burbank, Los Angeles County, Calif.) 2001;17(9):721-3.
2001: Michal Vrablík; Richard Ceska; Ales Horínek; Dan Wichterle
Absence of the R3531C mutation in the apoB gene in Czech hypercholesterolaemic patients.
Nutrition, metabolism, and cardiovascular diseases : NMCD 2001;11(3):212-4.
2001: Tomás Kvasnicka; Jan Kvasnicka; Richard Ceska; B Grauová; Michal Vrablík
Increasing plasma levels of soluble cell adhesion molecules (sE-Selectin, sP-Selectin and sICAM-1) in overweight adults with combined hyperlipidemia.
Sborník lékar̆ský 2001;102(4):473-7.
2001: Tomas Stulc; Richard Ceska
Cholesterol lowering and the vessel wall: new insights and future perspectives.
Physiological research / Academia Scientiarum Bohemoslovaca 2001;50(5):461-71.
2001: Michal Vrablík; Richard Ceska; Ales Horínek
Major apolipoprotein B-100 mutations in lipoprotein metabolism and atherosclerosis.
Physiological research / Academia Scientiarum Bohemoslovaca 2001;50(4):337-43.
2001: Jarmila Sulcová; Martin Hill; Z Masek; Richard Ceska; Alois Novácek; Richard Hampl; Luboslav Stárka
Effects of transdermal application of 7-oxo-DHEA on the levels of steroid hormones, gonadotropins and lipids in healthy men.
Physiological research / Academia Scientiarum Bohemoslovaca 2001;50(1):9-18.
2000: B Horejsí; Jirí Spácil; Richard Ceska; Michal Vrablík; Tomas Haas; Ales Horínek
The independent correlation of the impact of lipoprotein(a) levels and apolipoprotein E polymorphism on carotid artery intima thickness.
International angiology : a journal of the International Union of Angiology 2000;19(4):331-6.
2000: J Sobra; Richard Ceska; Jirí Spácil; Dan Wichterle; V Slézka; Ales Horínek; M Kvasilová; R Procházková; J Stanková
[Familial hyperlipoproteinemias--correlations between phenotypes and genotypes].
Casopís lékar̆ů c̆eských 2000;139 Suppl 1():13-5.
2000: Richard Ceska
[Therapeutic goals in hyperlipoproteinemia].
Vnitr̆ní lékar̆ství 2000;46(9):555-8.
2000: Michal Krsek; Richard Ceska; Ales Horínek; B Horejsí; V Weiss
Type III hyperlipoproteinaemia and primary amenorrhoea associated with severe hypothyroidism.
Acta paediatrica (Oslo, Norway : 1992) 2000;89(8):1023-4.
2000: Richard Ceska; Tomas Stulc
[Fenofibrate 250 SR Pharmavit in patients with mixed hyperlipoproteinemia. Results of a study of 189 patients from 13 centers in the Czech Republic].
Casopís lékar̆ů c̆eských 2000;139(12):369-73.
2000: Martin Haluzík; J Fiedler; Jara Nedvídková; Richard Ceska
Serum leptin levels in patients with hyperlipidemias.
Nutrition (Burbank, Los Angeles County, Calif.) 2000;16(6):429-33.
2000: Tomas Stulc; Richard Ceska; Ales Horínek; J Stĕpán
[Hyperlipoproteinemia, the Apo-E genotype and bone density].
Casopís lékar̆ů c̆eských 2000;139(9):267-71.
2000: Zdenek Hájek; Pavel Drbohlav; Richard Ceska; Ales Horínek; J Fiedler
[The spectrum of lipids in the intrauterine growth retarded fetus and in the parents].
Ceská gynekologie / Ceská lékarská spolecnost J. Ev. Purkyne 2000;65(3):123-7.
2000: Richard Ceska; Tomás Kvasnicka; T Haas; V Soska; Helena Vaverková
[Ciprofibrate in the treatment of combined hyperlipoproteinemia. Results in more than 600 patients from 23 centers in the Czech Republic].
Vnitr̆ní lékar̆ství 2000;46(3):157-60.
2000: Jarmila Sulcová; Martin Hill; Richard Hampl; Z Masek; Alois Novácek; Richard Ceska; Luboslav Stárka
Effects of transdermal application of DHEA on the levels of steroids, gonadotropins and lipids in men.
Physiological research / Academia Scientiarum Bohemoslovaca 2000;49(6):685-93.
2000: Tomas Stulc; Richard Ceska; Ales Horínek; Jan J Stepán
Bone mineral density in patients with apolipoprotein E type 2/2 and 4/4 genotype.
Physiological research / Academia Scientiarum Bohemoslovaca 2000;49(4):435-9.
2000: Richard Ceska; Michal Vrablík; Ales Horínek
Familial defective apolipoprotein B-100: a lesson from homozygous and heterozygous patients.
Physiological research / Academia Scientiarum Bohemoslovaca 2000;49 Suppl 1():S125-30.
2000: B Horejsí; Richard Ceska
Apolipoproteins and atherosclerosis. Apolipoprotein E and apolipoprotein(a) as candidate genes of premature development of atherosclerosis.
Physiological research / Academia Scientiarum Bohemoslovaca 2000;49 Suppl 1():S63-9.
1999: Jirí Spácil; Richard Ceska; Jan Petrásek; J Sobra
The effect of four-year hypolipidaemic treatment on the intimal thickness of the common carotid artery in patients with familiar hyperlipidaemia.
International angiology : a journal of the International Union of Angiology 1999;18(4):313-9.
1999: Michal Vrablík; Ales Horínek; Richard Ceska; Rudolf Poledne; M Hubácek
[Frequency of occurrence of apolipoprotein E isoforms in patients with various types of hyperlipoproteinemias].
Casopís lékar̆ů c̆eských 1999;138(16):491-4.
1999: A Horinek; Richard Ceska; J Sobra; Michal Vrablik
Familial defective apolipoprotein B-100 homozygote with premature coronary atherosclerosis. A case report.
Journal of internal medicine 1999;246(2):235-6.
1999: E Králíková; Richard Ceska; J Rames; J Sobra
[Negative aspects of the Western life style and possibilities of intervention in patients with familial combined hyperlipidemia].
Casopís lékar̆ů c̆eských 1999;138(8):239-44.
1999: J Sobra; Richard Ceska
[Genetic predisposition for the multiple metabolic syndrome. Part 4. Apolipoprotein E and lipoprotein (a)].
Casopís lékar̆ů c̆eských 1999;138(7):203-8.
1999: J Sobra; Richard Ceska
[Genetic predisposition in multiple metabolic syndrome. Part 3. Metabolism of lipids, lipoproteins and apolipoproteins].
Casopís lékar̆ů c̆eských 1999;138(5):136-41.
1999: E Králíková; Richard Ceska; J Rames
Diet, smoking, and blood lipids in patients with combined familial hyperlipidaemia.
Central European journal of public health 1999;7(1):19-23.
1999: J Sobra; Richard Ceska
[Genetic predisposition in multiple metabolic syndrome. Part 2. Candidate genes in type II diabetes mellitus].
Casopís lékar̆ů c̆eských 1999;138(3):70-4.
1999: Martin Haluzík; J Fiedler; Jara Nedvídková; Richard Ceska
Serum leptin concentrations in patients with combined hyperlipidemia: relationship to serum lipids and lipoproteins.
Physiological research / Academia Scientiarum Bohemoslovaca 1999;48(5):363-8.
1998: M Samánek; Z Urbanová; Richard Ceska
[What was not included in the recommendations for the diagnosis and therapy of hyperlipoproteinemia in childhood].
Casopís lékar̆ů c̆eských 1998;137(10):303-8.
1998: Z Urbanová; M Samánek; Richard Ceska; Renata Cífková; Rudolf Poledne; Hana Rosolová; V Soska; J Simon; Helena Vaverková; J Widimský; J Widimský; Z Zadák
[Recommendations for the diagnosis and therapy of hyperlipoproteinemia in childhood and adolescence developed by the Committee of the Czech Society for Atherosclerosis].
Casopís lékar̆ů c̆eských 1998;137(3):89-92.
1997: Jirí Spácil; Richard Ceska; Jan Petrásek; J Sobra
[The effect of 4 years' of hypolipemic treatment on the width of the common carotid artery intima in patients with familial hyperlipidemias].
Vnitr̆ní lékar̆ství 1997;43(11):722-7.
1997: Jirí Spácil; Richard Ceska; J Sobra; Jan Petrásek
Decreasing common carotid artery intimal thickness during hypolipidemic therapy.
Angiology 1997;48(9):761-7.
1997: Jirí Spácil; Richard Ceska; Jan Petrásek; J Sobra
[Favorable effect of treatment with statins on the intima of the common carotid artery in patients with familial hyperlipoproteinemia].
Casopís lékar̆ů c̆eských 1997;136(16):494-7.
1997: Richard Ceska; Renata Cífková; Rudolf Poledne; Hana Rosolová; V Soska; J Simon; J Sobra; Helena Vaverková; J Widimský; J Widimský; Z Zadák
[Recommendations for diagnosis and therapy of hyperlipoproteinemias in adulthood prepared by the Czech Atherosclerosis Society].
Casopís lékar̆ů c̆eských 1997;136(8):257-61.
1997: J Sobra; Ales Horínek; Richard Ceska; R Procházková; M Kvasilová
[Familial hypobetalipoproteinemia].
Casopís lékar̆ů c̆eských 1997;136(4):115-9.
1996: Richard Ceska; J Sobra; Jan Kvasnicka; R Procházková; M Kvasilová; T Haas
[The effect of micronized fenofibrate on lipid parameters and fibrinogen in heterozygous familial hypercholesterolemia and familial combined hyperlipidemia].
Casopís lékar̆ů c̆eských 1996;135(13):413-6.
1996: J Sobra; J Skrha; Richard Ceska
[Dyslipidemia in diabetes mellitus].
Vnitr̆ní lékar̆ství 1996;42(6):440-1.
1996: E Králíková; J Sobra; Richard Ceska; H Toschnerová; J Traurig
[Analysis of nutritional habits in patients with familial combined hyperlipidemia].
Casopís lékar̆ů c̆eských 1996;135(7):220-4.
1995: Marie Tomecková; V Danzig; Jan Bultas; J Sobra; Richard Ceska; H Toschnerová
[Silent myocardial ischemia in outpatients being treated for hyperlipoproteinemia].
Casopís lékar̆ů c̆eských 1995;134(16):514-7.
1995: Richard Ceska; J Sobra; R Procházková; M Kvasilová
[Simvastatin in the treatment of familial hypercholesterolemia].
Casopís lékar̆ů c̆eských 1995;134(10):310-3.
1995: Jirí Spácil; Richard Ceska; J Sobra; Jan Petrásek
[Decrease in common carotid artery intimal thickness after hypolipemic therapy].
Casopís lékar̆ů c̆eských 1995;134(10):306-9.
1995: Ales Horínek; V Slézka; J Sobra; Richard Ceska
[DNA analysis in heterozygotes in familial hypercholesterolemia].
Casopís lékar̆ů c̆eských 1995;134(8):234-9.
1995: Richard Ceska
[Pharmacotherapy of hyperlipoproteinemia in view of the newest European and American recommendations].
Vnitr̆ní lékar̆ství 1995;41(3):172-5.
1994: H Wilczek; J Sobra; Richard Ceska; V Justová; Z Jůzová; R Procházková; M Kvasilová
[Monitoring plasma levels of vitamin D metabolites in simvastatin (Zocor) therapy in patients with familial hypercholesterolemia].
Casopís lékar̆ů c̆eských 1994;133(23):727-9.
1994: Richard Ceska
[Familial apolipoprotein B-100 defect, a newly discovered lipid metabolism disorder].
Casopís lékar̆ů c̆eských 1994;133(22):686-9.
1993: H Wilczek; J Sobra; Richard Ceska; V Justová; R Procházková; M Kvasilová; Z Jůzová
[Therapy with fibrates and vitamin D metabolism].
Casopís lékar̆ů c̆eských 1993;132(20):630-2.
1993: Ales Horínek; J Sobra; Richard Ceska; P Paulasová
[Familial hypercholesterolemia from the aspect of DNA analysis].
Vnitr̆ní lékar̆ství 1993;39(10):946-50.
1993: H Toschnerová; Richard Ceska; J Sobra; J Traurig
[Duolip Forte--experience during a 6-month period of administration].
Casopís lékar̆ů c̆eských 1993;132(10):308-10.
1993: Jirí Spácil; Jan Petrásek; Richard Ceska; J Sobra
[Carotid artery and femoral artery disease in asymptomatic patients with various types of hyperlipoproteinemias and in healthy persons].
Casopís lékar̆ů c̆eských 1993;132(8):236-42.
1993: Richard Ceska
[Pharmacologic therapy of hyperlipoproteinemia and its pitfalls].
Vnitr̆ní lékar̆ství 1993;39(2):191-7.
1993: Jirí Spácil; Jan Petrásek; Richard Ceska; J Sobra
[The intima of the common carotid artery in patients with hyperlipoproteinemia].
Cor et vasa 1993;35(1):27-31.
1992: Z Písa; I Augustin; P Breinek; Richard Ceska; A Egnerová; P Hrabák; M Hromadová; H Malá; J Masopust; Rudolf Poledne
[Recommendations for the prevention of atherosclerosis and ischemic heart disease. Detection and treatment of persons with increased lipids in adulthood].
Casopís lékar̆ů c̆eských 1992;131(9):280-5.
1992: J Sobra; Richard Ceska
[Diseases of civilization from the aspect of evolution of the human diet].
Casopís lékar̆ů c̆eských 1992;131(7):193-7.
1992: Richard Ceska; J Sobra; H Toschnerová; J Traurig
[Combined therapy of hyperlipoproteinemia. Colestipol and gemfibrozil in the treatment of heterozygous familial hypercholesterolemia].
Casopís lékar̆ů c̆eských 1992;131(6):183-5.
1992: Richard Ceska; J Sobra; H Toschnerová; J Traurig
[Colestipol in the treatment of heterozygous familial hypercholesterolemia].
Casopís lékar̆ů c̆eských 1992;131(4):118-20.
1991: Václav Hána; Josef Marek; Richard Ceska; J Sobra; Richard Hampl; L Stárka
Influence of testosterone isobutyrate on serum lipoproteins during replacement therapy of hypogonadal men.
Czechoslovak medicine 1991;14(2):123-8.
1990: Richard Ceska; J Sobra; R Procházková; M Kvasilová
[Etolip and Lipanthyl in the treatment of hyperlipoproteinemia].
Vnitr̆ní lékar̆ství 1990;36(4):363-7.
1990: Richard Ceska; J Sobra; P Procházková; M Kvasilová
[Bezalip in the treatment of hyperlipoproteinemia].
Casopís lékar̆ů c̆eských 1990;129(1):20-2.
1989: J Sobra; J Páv; Richard Ceska
[Hyperlipoproteinemia and the genetic epidemiology of diabetes mellitus].
Casopís lékar̆ů c̆eských 1989;128(50):1575-9.
1989: Richard Ceska; J Sobra; M Kvasilová; R Procházková
[Apolipoprotein B, a risk factor in ischemic heart disease: possibilities of its determination using Czechoslovak-manufactured antisera].
Sborník lékar̆ský 1989;91(11-12):334-8.
1989: Richard Ceska; J Sobra
[Gemfibrozil in the treatment of hyperlipoproteinemia].
Vnitr̆ní lékar̆ství 1989;35(10):967-71.
1989: H Wilczek; J Sobra; V Justová; Richard Ceska; Z Jůzová; R Procházková; M Kvasilová; V Pacovský
[Iatropathogenic effect of Mevacor on vitamin D metabolism].
Casopís lékar̆ů c̆eských 1989;128(40):1254-6.
1989: Richard Ceska; J Sobra; R Procházková; M Kvasilová
[Treatment of familial hypercholesterolemia using Mevacor. Initial experience].
Casopís lékar̆ů c̆eských 1989;128(21):661-3.
1988: J Sobra; Richard Ceska
[Familial hypercholesterolemia--a receptor disease].
Casopís lékar̆ů c̆eských 1988;127(33):1033-6.
1988: Richard Ceska; M Aschermann; J Sobra; P Pinkava; J Vancura
[Coronarography in patients with hyperlipoproteinemia].
Sborník lékar̆ský 1988;90(7):213-7.
1988: K Pavelka; Richard Ceska; J Sobra; S Alusík
[Hyperlipoproteinemia in patients with uric arthritis. The effect of treatment on the disease].
Casopís lékar̆ů c̆eských 1988;127(13):394-7.
1988: S Alusík; K Pavelka; Richard Ceska; J Sobra
[Ischemic heart disease and risk factors in patients with gout].
Vnitr̆ní lékar̆ství 1988;34(2):116-21.
1988: V A Metel'skaya; Richard Ceska; N V Perova; J Sobra
Blood plasma apolipoproteins A-I and B in different types of hyperlipoproteinaemia: comparative analysis of population groups in Moscow and Prague.
Cor et vasa 1988;30(3):168-76.
1987: Richard Ceska; K Pavelka; J Sobra
[Hyperlipoproteinemia in patients with manifest gout].
Sborník lékar̆ský 1987;89(2-3):67-72.